Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 8/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | VDR | P11473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9363550 | 0.82 | POLB (0.49) | POLBGAAGLATSHRPDE3B | |
| SCHEMBL9366740 | 0.81 | PDE3B (0.48) | POLBGAAGLATSHRPDE3B | |
| SCHEMBL25866716 | 0.81 | ADRA2B (0.36) | ALDH1A1MAPTLMNAARVDR | |
| SCHEMBL9366724 | 0.81 | ALDH1A1 (0.49) | POLBGAAGLATSHRPDE3B | |
| SCHEMBL1927879 | 0.80 | GAA (0.50) | POLBGAAGLATSHRPDE3B | |
| SCHEMBL9362895 | 0.80 | PDE3B (0.49) | POLBGAAGLATSHRPDE3B | |
| SCHEMBL9023870 | 0.80 | POLB (0.43) | POLBGAAGLATSHRPDE3B | |
| SCHEMBL9023734 | 0.80 | POLB (0.43) | POLBGAAGLATSHRPDE3B | |
| Iodide SCHEMBL7164050 | 0.79 | POLB (0.42) | POLBGAAGLATSHRPDE3B | |
| SCHEMBL9363417 | 0.79 | PDE3B (0.48) | POLBGAAGLATSHRPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | POLB 2403/4885GAA 1807/4885GLA 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.